Table 3.
Mapping of anti-RBD mAbs by binding competition assaysa
| Group | Competing mAb | % Inhibition of binding by biotinylated mAb |
||||
|---|---|---|---|---|---|---|
| 10E 7 (I) | 11E 12 (III) | 33G4 (V) | 45B5 (VI) | Epitope | ||
| A | S6 | 58.2 | 1.8 | −2.4 | 0.5 | Conf I-like |
| S9 | 64.2 | 6.1 | −1.1 | 3.0 | Conf I-like | |
| S37 | 67.9 | 3.7 | −1.8 | 5.2 | Conf I-like | |
| S40 | 92.2 | 7.4 | 2.5 | 19.7 | Conf I-like | |
| S50 | 78.8 | 2.3 | 2.3 | 3.6 | Conf I-like | |
| B | S20 | 0.4 | 91.8 | −3.6 | 9.0 | Conf III-like |
| S38 | −2.0 | 94.2 | −2.1 | 6.8 | Conf III-like | |
| S53 | 20.3 | 90.8 | 1.9 | −0.8 | Conf III-like | |
| C | S44 | 6.9 | −17.8 | −1.2 | 94.7 | Conf IV-like |
| D | S25 | 38.9 | 8.5 | −1.5 | 20.1 | Conf VII |
| E | S29 | 3.6 | 14.0 | −1.3 | 8.0 | Linear |
| S33 | 6.2 | 15.6 | −2.9 | 13.7 | Linear | |
a
Competing mAbs were tested at 100 μg/ml for the ability to block binding of the biotinylated mAbs to the RBD-Fc in ELISA. Greater than 40% inhibition was considered positive competition (values in bold). Negative numbers indicate increased binding of the biotinylated reagent.